PodcastsCienciasCell & Gene: The Podcast

Cell & Gene: The Podcast

Erin Harris
Cell & Gene: The Podcast
Último episodio

132 episodios

  • Cell & Gene: The Podcast

    Advancing Early Detection in Rare Cancers with Catriona Jamieson, M.D., Ph.D.

    09/04/2026 | 20 min
    We love to hear from our listeners. Send us a message.
    On episode 126 of Cell & Gene: The Podcast, Host Erin Harris welcomes Catriona Jamieson, M.D., Ph.D, Director of the UC San Diego Sanford Stem Cell Institute and Professor of Medicine at the School of Medicine. They explore how shifting the medical mindset from “common horses” to rare “zebras” is unlocking earlier detection and more effective treatment of diseases like myelofibrosis. Dr. Jamieson explains how subtle, often overlooked symptoms can mask serious underlying conditions, and how advances in genomic testing are enabling clinicians to identify disease-driving mutations sooner. They cover groundbreaking progress in targeted therapies, which aim to stop cancer progression and overcome treatment resistance. 
    Subscribe to the podcast!
    Apple  |  Spotify |  YouTube
    Visit my website: Cell & Gene
    Connect with me on LinkedIn
  • Cell & Gene: The Podcast

    Regulatory Flexibility in CGT: Key Shifts and Implications with Monika Swietlicka

    26/03/2026 | 27 min
    We love to hear from our listeners. Send us a message.
    On episode 125 of Cell & Gene: The Podcast, Host Erin Harris talks to Halloran Consulting Group's Monika Swietlicka to discuss how the FDA is increasing flexibility in cell and gene therapy development without lowering evidentiary standards, emphasizing a risk-based, holistic approach. They also explore what this means for developers, from platform strategies and global regulatory divergence to the growing role of patient advocacy and the need for early, integrated planning.
    Subscribe to the podcast!
    Apple  |  Spotify |  YouTube
    Visit my website: Cell & Gene
    Connect with me on LinkedIn
  • Cell & Gene: The Podcast

    Scaling CRISPR for Rare Disease with Aurora Therapeutics' Dr. Edward Kaye

    12/03/2026 | 28 min
    We love to hear from our listeners. Send us a message.
    On episode 124 of Cell & Gene: The Podcast, Aurora Therapeutics' CEO Dr. Edward Kaye discusses the company’s strategy for translating CRISPR gene editing into scalable, commercially viable medicines for rare diseases. Aurora is initially targeting phenylketonuria (PKU) using a platform approach that leverages shared components, such as lipid nanoparticles and base editors, while customizing guide RNAs for specific mutations. Dr. Kaye explains how trials, regulatory flexibility, and optimized manufacturing could make it possible to treat many genetic variants efficiently and cost-effectively. Ultimately, Aurora aims to build a repeatable model that expands gene editing access to larger rare-disease populations while keeping patients at the center of development.
    Subscribe to the podcast!
    Apple  |  Spotify |  YouTube
    Visit my website: Cell & Gene
    Connect with me on LinkedIn
  • Cell & Gene: The Podcast

    Simplifying Friction in Cell Therapy Clinical Trials with Dr. Panteli Theocharous

    26/02/2026 | 34 min
    We love to hear from our listeners. Send us a message.
    In episode 123 of Cell & Gene: The Podcast, Host Erin Harris talks to Dr. Panteli Theocharous, FIBMS, M.S., Ph.D., FRCPath, about the patient journey in cell therapy trials. They pinpoint key friction points, such as delayed referrals, unpredictable vein-to-vein timelines, and burdensome long-term follow-up, while sharing actionable strategies for simplification. These strategies range from upstream trial design and streamlined consent processes to standardized logistics, hybrid monitoring models, honest risk communication, and engaging patients as true partners in real-world evidence generation.
    Subscribe to the podcast!
    Apple  |  Spotify |  YouTube
    Visit my website: Cell & Gene
    Connect with me on LinkedIn
  • Cell & Gene: The Podcast

    Inside a Breakthrough HER2 Immunotherapy for PMO with OS Therapies’ Paul Romness

    12/02/2026 | 14 min
    We love to hear from our listeners. Send us a message.
    In episode 122 of Cell & Gene: The Podcast, Host Erin Harris talks to Paul Romness, CEO of OS Therapies, to learn the company’s mission to address the severe unmet need in pulmonary metastatic osteosarcoma (PMO), a rare pediatric cancer with no established standard of care once it metastasizes. Romness explains how OS Therapies’ off-the-shelf HER2-targeted immunotherapy aims to significantly improve outcomes by stimulating a robust immune response with minimal side effects. He highlights results from a multicenter Phase 2B trial showing markedly improved overall survival rates compared to historical outcomes, details the company’s constructive regulatory interactions with the FDA, and underscores the value of comparative canine biomarkers in development.
    Subscribe to the podcast!
    Apple  |  Spotify |  YouTube
    Visit my website: Cell & Gene
    Connect with me on LinkedIn

Más podcasts de Ciencias

Acerca de Cell & Gene: The Podcast

Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.
Sitio web del podcast

Escucha Cell & Gene: The Podcast, Hidden Brain y muchos más podcasts de todo el mundo con la aplicación de radio.net

Descarga la app gratuita: radio.net

  • Añadir radios y podcasts a favoritos
  • Transmisión por Wi-Fi y Bluetooth
  • Carplay & Android Auto compatible
  • Muchas otras funciones de la app

Cell & Gene: The Podcast: Podcasts del grupo

Aplicaciones
Redes sociales
v8.8.6| © 2007-2026 radio.de GmbH
Generated: 4/11/2026 - 12:34:24 AM